Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chaitanya Pabbati

Psychiatry San Diego, CA Medical Doctor

NPI 1710237391 CMS profile 1038528

5060 Shoreham Pl Ste 330, San Diego, CA 92122

Open in the dashboard

General payments

$7,427

333 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chaitanya Pabbati of San Diego, CA is reported in the CMS Open Payments database as having received $7,427 across 333 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,553 53
2024 General $1,344 49
2023 General $1,106 53
2022 General $1,481 80
2021 General $1,090 53
2020 General $194 9
2019 General $660 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chaitanya Pabbati
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Chaitanya Pabbati were reported at $1,553. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Chaitanya Pabbati Psychiatry median Middle half National median
2019 $660 $184 $59–$605 $163
2020 $194 $119 $36–$372 $114
2021 $1,090 $143 $43–$576 $132
2022 $1,481 $153 $50–$590 $149
2023 $1,106 $170 $56–$651 $160
2024 $1,344 $179 $57–$673 $164
2025 $1,553 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $1,535 64 payments
  2. Otsuka America Pharmaceutical, Inc. $1,016 51 payments
  3. Lundbeck LLC $757 36 payments
  4. AbbVie, Inc. $695 34 payments
  5. ITI, Inc. $574 22 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $568 30 payments
  7. Sunovion Pharmaceuticals Inc. $334 15 payments
  8. Neurocrine Biosciences, Inc. $293 11 payments
  9. Indivior Inc. $216 9 payments
  10. Vanda Pharmaceuticals Inc. $202 13 payments
  11. Other $1,239 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,329 329 payments
  2. Education $98 4 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $1,306 43 payments
  2. REXULTI Psychiatry $893 43 payments
  3. REXULTI Psychiatry $716 34 payments
  4. VRAYLAR Neuroscience $520 26 payments
  5. TRINTELLIX $481 26 payments
  6. CAPLYTA $461 18 payments
  7. INVEGA SUSTENNA $431 28 payments
  8. LATUDA $334 15 payments
  9. INGREZZA $226 7 payments
  10. VRAYLAR Neuroscience $207 10 payments
  11. Other $2,526 124 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

333 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record